Patient characteristics
| Diagnosis . | n . | F/M . | Median age, y* . | Median hemoglobin, g/dL . | Median platelet count, ×109/L . | Median white blood cell count, ×109/L . | Patients with a known KIT mutation, % . | Median % of MCs in BM sections by IHC† . | Median serum tryptase, ng/mL . | Median alkaline phosphatase, U/L . |
|---|---|---|---|---|---|---|---|---|---|---|
| CM | 15 | 2.0 | 45 | 13.8 | 236 | 6.1 | 45.5 | <1 | 12.0 | 75 |
| ISM | 79 | 1.2 | 47 | 14.0 | 238 | 6.5 | 85.3 | 10.0 | 37.3 | 72 |
| SSM | 7 | 2.5 | 47 | 13.7 | 221 | 6.2 | 100.0 | 40.0 | 252.0 | 124 |
| SM-AHN | 40 | 0.3 | 65 | 10.7 | 75 | 9.3 | 84.2 | 15.0 | 105.5 | 130 |
| ASM | 12 | 0.5 | 58 | 10.3 | 106 | 5.9 | 83.3 | 25.0 | 113.5 | 194 |
| MCL | 8 | 0.6 | 60 | 10.0 | 61 | 5.3 | 75.0 | 75.0 | 431.5 | 101 |
| RBM | 5 | All M | 68 | 11.2 | 199 | 6.1 | — | — | — | — |
| ICUS | 3 | 0.5 | 61 | 14.3 | 86 | 3.7 | — | — | — | — |
| HD | 2 | All F | 40 | 10.2 | 497 | 12.1 | — | — | — | — |
| MGUS | 4 | 0.3 | 63 | 14.8 | 207 | 8.0 | — | — | — | — |
| AL amyloidosis | 2 | 1 | 64 | 12.3 | 279 | 7.7 | — | — | — | — |
| B-NHL | 36 | 0.4 | 66 | 11.7 | 237 | 7.8 | — | — | — | — |
| T-NHL | 5 | 1.5 | 42 | 13.5 | 257 | 10.0 | — | — | — | — |
| Healthy controls | 15 | 2.0 | 32 | — | — | — | — | — | — | — |
| Diagnosis . | n . | F/M . | Median age, y* . | Median hemoglobin, g/dL . | Median platelet count, ×109/L . | Median white blood cell count, ×109/L . | Patients with a known KIT mutation, % . | Median % of MCs in BM sections by IHC† . | Median serum tryptase, ng/mL . | Median alkaline phosphatase, U/L . |
|---|---|---|---|---|---|---|---|---|---|---|
| CM | 15 | 2.0 | 45 | 13.8 | 236 | 6.1 | 45.5 | <1 | 12.0 | 75 |
| ISM | 79 | 1.2 | 47 | 14.0 | 238 | 6.5 | 85.3 | 10.0 | 37.3 | 72 |
| SSM | 7 | 2.5 | 47 | 13.7 | 221 | 6.2 | 100.0 | 40.0 | 252.0 | 124 |
| SM-AHN | 40 | 0.3 | 65 | 10.7 | 75 | 9.3 | 84.2 | 15.0 | 105.5 | 130 |
| ASM | 12 | 0.5 | 58 | 10.3 | 106 | 5.9 | 83.3 | 25.0 | 113.5 | 194 |
| MCL | 8 | 0.6 | 60 | 10.0 | 61 | 5.3 | 75.0 | 75.0 | 431.5 | 101 |
| RBM | 5 | All M | 68 | 11.2 | 199 | 6.1 | — | — | — | — |
| ICUS | 3 | 0.5 | 61 | 14.3 | 86 | 3.7 | — | — | — | — |
| HD | 2 | All F | 40 | 10.2 | 497 | 12.1 | — | — | — | — |
| MGUS | 4 | 0.3 | 63 | 14.8 | 207 | 8.0 | — | — | — | — |
| AL amyloidosis | 2 | 1 | 64 | 12.3 | 279 | 7.7 | — | — | — | — |
| B-NHL | 36 | 0.4 | 66 | 11.7 | 237 | 7.8 | — | — | — | — |
| T-NHL | 5 | 1.5 | 42 | 13.5 | 257 | 10.0 | — | — | — | — |
| Healthy controls | 15 | 2.0 | 32 | — | — | — | — | — | — | — |
AL, amyloid light chain; B-NHL, B-cell non-Hodgkin lymphoma; F, female; HD, Hodgkin disease (without BM involvement); ICUS, idiopathic cytopenia of undetermined significance; M, male; MGUS, monoclonal gammopathy of undetermined significance; n, number; RBM, normal reactive BM (suspected lymphoproliferative disorder); T-NHL, T-cell non-Hodgkin lymphoma; y, years.
At the time of BM or serum sampling. In most cases, BM was obtained at diagnosis.
Percentage of MCs of all nucleated cells in the BM was determined by IHC using an antibody against tryptase.